SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:oru-85204"
 

Sökning: id:"swepub:oai:DiVA.org:oru-85204" > Influenza vaccinati...

  • Joona, Therse BjörkinDepartment of Oncology, Västerås Central Hospital, Västerås, Sweden,Västerås Hosp, Dept Oncol, Västerås, Sweden. (författare)

Influenza vaccination in breast cancer patients during subcutaneous trastuzumab in adjuvant setting

  • Artikel/kapitelEngelska2020

Förlag, utgivningsår, omfång ...

  • 2020-08-01
  • Springer,2020
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:oru-85204
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-85204URI
  • https://doi.org/10.1007/s10549-020-05815-yDOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-439244URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agency:Örebro University
  • Background: Despite the current recommendation for influenza vaccination in cancer patients with active oncological therapy, limited data are available on the efficacy of vaccination in cancer patients receiving targeted therapies. We aimed to investigate the immunogenicity and tolerability of influenza vaccination in breast cancer patients treated with trastuzumab in adjuvant setting.Methods: A prospective open-label multicenter study was performed including patients with breast cancer during trastuzumab treatment in adjuvant setting and healthy controls. Blood samples were taken before, 4 weeks after, and 12 weeks after a single dose of trivalent influenza vaccine containing inactivated A/California/7/2009 (H1N1) pdm09, A/Hongkong4801/2014 (H3N2), and B/Brisbane/60/2008. Levels of serum antibody titers to hemagglutinin for H1N1 and influenza B strains were measured.Results: Twenty breast cancer patients and 37 controls were included in the study. No difference in seroprotection rate between trastuzumab-treated patients and controls was observed for either H1N1 (100% in both groups) or B strain (78.9% vs. 89.2%,pvalue = 0.423). A statistically significant increase in geometric mean titers from baseline was seen in both groups and was evident both 4 weeks and 12 weeks after vaccination. Adverse events in the trastuzumab-treated group were uncommon and mild with only one serious adverse event not related to vaccination.Conclusion: Breast cancer patients treated with trastuzumab in adjuvant setting seem to benefit from influenza vaccination in terms of immunogenicity without increasing the risk for adverse events. The current data support the recommendation to offer influenza vaccination in breast cancer patients treated with this type of targeted therapy.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Digkas, EvangelosDepartment of Oncology, Mälarsjukhuset, Eskilstuna, Sweden,Malarsjukhuset, Dept Oncol, Eskilstuna, Sweden. (författare)
  • Wennstig, Anna-KarinDepartment of Oncology, Sundsvall Hospital, Sundsvall, Sweden,Sundsvall Hosp, Dept Oncol, Sundsvall, Sweden. (författare)
  • Nyström, Karin,1978-Örebro universitet,Institutionen för medicinska vetenskaper,Department of Oncology,Örebro Univ, Fac Med & Hlth, Dept Oncol, S-70182 Örebro, SE, Sweden.(Swepub:oru)kinm (författare)
  • Nearchou, AndreasDepartment of Oncology, Mälarsjukhuset, Eskilstuna, Sweden,Malarsjukhuset, Dept Oncol, Eskilstuna, Sweden. (författare)
  • Nilsson, CeciliaDepartment of Oncology, Västerås Central Hospital, Västerås, Sweden,Västerås Hosp, Dept Oncol, Västerås, Sweden. (författare)
  • Pauksen, KarlisUppsala universitet,Infektionsmedicin(Swepub:uu)karlpauk (författare)
  • Valachis, Antonis,1984-Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Oncology,Örebro Univ, Fac Med & Hlth, Dept Oncol, S-70182 Örebro, SE, Sweden.(Swepub:oru)asvs (författare)
  • Department of Oncology, Västerås Central Hospital, Västerås, SwedenVästerås Hosp, Dept Oncol, Västerås, Sweden. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Breast Cancer Research and Treatment: Springer184:1, s. 45-520167-68061573-7217

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy